Do benzodiazepines reduce the effectiveness of exposure therapy for posttraumatic stress disorder?

Journal of Clinical Psychiatry

Volumn 74, Issue 12, 2013, Pages 1241-1248

  Rosen, Craig S ^a,b,c,d   Greenbaum, Mark A ^c   Schnurr, Paula P ^a,e,f   Holmes, Tyson H ^a,b   Brennan, Penny L ^d   Friedman, Matthew J ^a,e,f  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HSR and D Center for Innovation to Implementation   (United States)

^e NATIONAL CENTER FOR PTSD   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; DSM-IV; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTILEVEL ANALYSIS; POST HOC ANALYSIS; POSTTRAUMATIC STRESS DISORDER; PRESENT CENTERED PSYCHOTHERAPY; PRIORITY JOURNAL; PROLONGED EXPOSURE PSYCHOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SOLDIER; TREATMENT RESPONSE; VETERAN;

ADULT; BENZODIAZEPINES; COMBINED MODALITY THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MIDDLE AGED; MILITARY PERSONNEL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 84891456143     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08592     Document Type: Article

References (40)

1. Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184
2. Schell TL. Survey of individuals previously deployed for OEF/OIF. In: Tanielian TL, ed. Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery. Santa Monica, CA: Rand; 2008: 87-115.
3. Tolin DF, Foa EB. Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. Psychol Bull. 2006;132(6):959-992.
4. Schnurr PP, Lunney CA, Bovin MJ, et al. Posttraumatic stress disorder and quality of life: extension of findings to veterans of the wars in Iraq and Afghanistan. Clin Psychol Rev. 2009;29(8):727-735.
5. Dedert EA, Calhoun PS, Watkins LL, et al. Posttraumatic stress disorder, cardiovascular, and metabolic disease: a review of the evidence. Ann Behav Med. 2010;39(1):61-78.
6. Del Gaizo AL, Elhai JD, Weaver TL. Posttraumatic stress disorder, poor physical health and substance use behaviors in a national trauma-exposed sample. Psychiatry Res. 2011;188(3):390-395.
7. Forbes D, Creamer M, Bisson JI, et al. A guide to guidelines for the treatment of PTSD and related conditions. J Trauma Stress. 2010;23(5):537-552.
8. Bradley R, Greene J, Russ E, et al. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162(2):214-227.
9. Foa EB, Hembree EA, Rothbaum BO. Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences: Therapist Guide. Oxford, UK: Oxford University Press; 2007.
10. Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010; 30(6):635-641.
11. Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. JAMA. 2007;297(8):820-830.
12. de Kleine RA, Hendriks GJ, Kusters WJ, et al. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry. 2012;71(11):962-968.
13. Eftekhari A, Ruzek JI, Crowley JJ, et al. Effectiveness of national implementation of prolonged exposure therapy in Veterans Affairs care. JAMA Psychiatry. 2013;70(9):949-955.
14. Lund BC, Bernardy NC, Alexander B, et al. Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3): 292-296.
15. Harpaz-Rotem I, Rosenheck RA, Mohamed S, et al. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv. 2008;59(10):1184-1190.
16. Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with posttraumatic stress disorder. Psychiatr Serv. 2003;54(12):1618-1621.
17. VA/DoD Clinical Practice Guideline for Management of Post-Traumatic Stress. Version 2.0 2010. US Department of Veterans Affairs Website. Washington, DC. http://www.healthquality.va.gov/PostTraumaticStressDisorderPTSD.asp. Updated May 29, 2013. Accessed December 12, 2012.
18. Jain S, Greenbaum MA, Rosen CS. Concordance between psychotropic prescribing for veterans with PTSD and clinical practice guidelines. Psychiatr Serv. 2012;63(2):154-160.
19. Otto MW, McHugh K, Kantak KM. Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes. Clin Psychol Sci Pract. 2010;17(2):91-103.
20. Makkar SR, Zhang SQ, Cranney J. Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. Neuropsychopharmacology. 2010;35(8):1625-1652.
21. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45-58.
22. Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29(8): 639-658.
23. Yang YL, Chao PK, Ro LS, et al. Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology. 2007;32(5):1042-1051.
24. Başoǧlu M, Marks IM, Kiliç C, et al. Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry. 1994;164(5):652-659.
25. Hetrick SE, Purcell R, Garner B, et al. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010;7(7):CD007316.
26. van Minnen A, Arntz A, Keijsers GPJ. Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout. Behav Res Ther. 2002;40(4):439-457.
27. Spiegel DA, Bruce TJ. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Am J Psychiatry. 1997;154(6):773-781.
28. Weathers FW, Keane TM, Davidson JRT. Clinician-Administered PTSD Scale: a review of the first ten years of research. Depress Anxiety. 2001;13(3): 132-156.
29. Blanchard EB, Jones-Alexander J, Buckley TC, et al. Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther. 1996;34(8):669-673.
30. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571.
31. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), 1: conceptual framework and item selection. Med Care. 1992; 30(6):473-483.
32. Gray MJ, Litz BT, Hsu JL, et al. Psychometric properties of the Life Events Checklist. Assessment. 2004;11(4):330-341.
33. Schnurr PP, Friedman MJ, Engel CC, et al. Issues in the design of multisite clinical trials of psychotherapy: VA Cooperative Study No. 494 as an example. Contemp Clin Trials. 2005;26(6):626-636.
34. Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581-592.
35. Schafer JL. Analysis of Incomplete Multivariate Data. New York, NY: Chapman & Hall; 1997.
36. Wolfinger R, O?Connell M. Generalized linear mixed models: a pseudolikelihood approach. J Statist Comput Simulation. 1993;48(3-4):233-243.
37. Research-supported psychological treatments: posttraumatic stress disorder. Society of Clinical Psychology, American Psychological Association Division 12 Website. http://www.div12.org/PsychologicalTreatments/disorders/ptsd main.php. Updated 2008. Accessed October 11, 2013.
38. Pietrzak RH, Goldstein RB, Southwick SM, et al. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456-465.
39. Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940-947.
40. Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with posttraumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs. 2006;20(7):567-590.